Biotinylated Human LAIR1 / CD305 Protein, Fc,Avitag™ (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
LA1-H82F5-25ug
$360.00
LA1-H82F5-200ug
$1565.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    LAIR1, CD305

  • Source

    Biotinylated Human LAIR-1, Fc,Avitag (LA1-H82F5) is expressed from human 293 cells (HEK293). It contains AA Gln 22 - His 163 (Accession # Q6GTX8-1).

    Predicted N-terminus: Gln 22

    Request for sequence
  • Molecular Characterization

    LAIR-1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 43.6 kDa. The protein migrates as 50-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    LAIR-1 SDS-PAGE

    Biotinylated Human LAIR-1, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    LAIR-1 SEC-MALS

    The purity of Biotinylated Human LAIR-1, Fc,Avitag (Cat. No. LA1-H82F5) is more than 95% and the molecular weight of this protein is around 85-113 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     LAIR-1 ELISA

    Immobilized Native Human Collagen I protein at 10 μg/mL (100 μL/well) can bind Biotinylated Human LAIR-1, Fc,Avitag (Cat. No. LA1-H82F5) with a linear range of 0.01-0.625 μg/mL (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is constitutively expressed on the majority of human peripheral blood mononuclear leukocytes. LAIR-1 or CD305 is a transmembrane glycoprotein with a single immunoglobulin-like domain and a cytoplasmic tail containing two immune receptor tyrosine-based inhibitory motifs. LAIR-1 recruits SHP-1 and SHP-2 phosphatases upon activation, and cross-linking of the LAIR-1 antigen on natural killer (NK) cells results in strong inhibition of NK cell–mediated cytotoxicity.
Functions as an inhibitory receptor that plays a constitutive negative regulatory role on cytolytic function of natural killer (NK) cells, B-cells and T-cells. Activation by Tyr phosphorylation results in recruitment and activation of the phosphatases PTPN6 and PTPN11. It also reduces the increase of intracellular calcium evoked by B-cell receptor ligation.Diseases associated with LAIR1 include Chronic Active Epstein-Barr Virus Infection and Palindromic Rheumatism.

Recent Advances

 
Drug Development Progress
  • English Name:

    Leukocyte-associated immunoglobulin-like receptor 1

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    2 Details

  • Highest Development Stage:

    Phase 2 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland